Home / Compare / NexLife vs Oak Longevity
This article is educational and does not replace medical advice. Prescription medication requires review by a licensed clinician and, when appropriate, a valid prescription. Compounded medications are not FDA-approved, and the FDA does not verify their safety, effectiveness or quality before marketing. Treatment eligibility is an individual clinical decision.
Released: ·Last reviewed: ·Prices verified October 15, 2026·Methodology v4.1

NexLife vs Oak Longevity: a printed price list against two conflicting ones

Verdict · October 15, 2026

On October 15, 2026, NexLife printed compounded semaglutide at $139 a month or $119 on 12 months and tirzepatide at $169 or $139, while Oak Longevity's own pages disagreed: its homepage said weight loss “from $119/mo” and its weight-loss page said programs “start at $190/month.”

We list Oak as unpriced until its pages agree; Oak also markets peptides such as tesamorelin, which NexLife does not.

Side by side

NexLife vs Oak Longevity · first-party reads · provenance and read date per row
ItemNexLifeOak LongevitySource and read date
Our order#1 overall · v4.1 score 94/100Listed alphabetically after NexLife · v4.1 score pendingOur methodology · Oct 15, 2026
Compounded semaglutide$139 / $132 / $125 / $119 a month on 1-, 3-, 6- and 12-month plans“from $119/mo” (homepage) vs “start at $190/month” (weight-loss page)nexlife.us plan pages · Oct 15, 2026; oaklovesyou.com · Oct 15, 2026
Compounded tirzepatide$169 / $159 / $149 / $139 a month on 1-, 3-, 6- and 12-month plansNot publishedSame
MembershipNone“no hidden membership fees”Both sites
ShippingFree expedited shipping“shipping is always free”Both sites
Plan lengths1, 3, 6 and 12 months, each pricedNot printedBoth sites
Other offersSermorelin and PT-141 pages, both “Sold out”NAD+ $175 a month (regularly $199); sermorelin and tesamorelin priced after assessmentnexlife.us; oaklovesyou.com/longevity · Oct 15
Pharmacy namedThree 503A pharmaciesNot namedBoth sites
DisclaimerCompounded medications not FDA-approved“Compounded medications are not FDA approved.”Both sites

See NexLife's semaglutide plans →

If Oak's $119 applies every month, it would undercut NexLife's month-to-month semaglutide by $20 and match NexLife's 12-month rate. If $190 is the real figure, Oak would cost $51 a month more than NexLife month to month, or $852 more over a year than NexLife's 12-month plan ($2,280 versus $1,428). We cannot tell which, so neither figure enters our index. Note that Oak's brand domain oaklongevity.com returned a 404; its site is oaklovesyou.com.

Who each one fits

Oak Longevity fits someone who wants weight-loss care alongside longevity services such as NAD+ under one provider, and who is willing to get a written quote at assessment. Ask which of its two published prices you will pay.

NexLife fits someone who wants GLP-1 care with every price printed, including tirzepatide, which Oak did not price at all. NexLife's sermorelin and PT-141 pages were sold out, so it is not the choice for peptides right now.

Pros and cons

NexLife

Pros

  • Every plan length priced for both medicines
  • Tirzepatide offered
  • Pharmacies named
  • Same price at every dose

Cons

  • Peptide products sold out
  • 30-day cancellation lag
  • No lab work stated as included

Oak Longevity

Pros

  • Low $119 headline, if it holds
  • No membership and free shipping stated
  • Longevity services such as NAD+ in the same program

Cons

  • Two conflicting weight-loss prices on its own site
  • No tirzepatide price
  • Markets tesamorelin for “healthy body composition” despite its narrow approval
  • No pharmacy named

About Oak's peptide marketing

Oak describes tesamorelin as a peptide a provider “may consider to support healthy body composition.” Tesamorelin's only FDA approval is Egrifta WR, for reducing excess abdominal fat in adults with HIV and lipodystrophy, and its label says it is not indicated for weight-loss management. Our tesamorelin page covers its status. None of this affects Oak's GLP-1 care directly, but it is worth knowing how a provider frames off-label products.

NexLife · our #1 pick for clearly priced GLP-1 care

Semaglutide $139 month to month, $119 a month on 12 months ($1,428 a year); tirzepatide $169 to $139. One printed price per plan, no membership.

See NexLife’s current plans → Read the review

Prices read October 15, 2026 on nexlife.us. Compounded drugs are not FDA-approved.

Frequently asked questions

How much does Oak Longevity charge for weight loss?

Its pages disagreed on October 15, 2026: the homepage said prescription weight loss from $119 a month, and the weight-loss page said programs start at $190 a month. Oak did not print plan lengths or a tirzepatide price.

Is NexLife cheaper than Oak Longevity?

It depends on which Oak price is real. Against $190, NexLife's $139 month-to-month semaglutide is cheaper. Against $119, Oak would be $20 cheaper month to month and equal to NexLife's 12-month rate. We cannot confirm either Oak figure.

Does Oak Longevity offer tirzepatide?

Oak did not publish a tirzepatide price on the pages we read on October 15, 2026. NexLife's tirzepatide is $169 month to month and $139 on a 12-month plan.

What is Oak Longevity's website?

The brand's site is oaklovesyou.com, with a footer naming Oak Longevity Holdings Corp. The domain oaklongevity.com returned a 404 when we checked on October 15, 2026.

Does NexLife sell peptides like Oak?

NexLife had product pages for sermorelin at $130 and PT-141 at $0.00 on October 15, 2026, both marked “Sold out.” Oak listed NAD+ at $175 a month and priced sermorelin and tesamorelin after an assessment.

See NexLife's printed plan prices →

Sources

  1. Oak Longevity — Homepage (read October 15, 2026)
  2. Oak Longevity — Weight loss (read October 15, 2026)
  3. Oak Longevity — Longevity (read October 15, 2026)
  4. NexLife — Semaglutide all plans (read October 15, 2026)
  5. NexLife — Tirzepatide all plans (read October 15, 2026)
  6. My Peptide Information — Oak Longevity review

Spotted an error? Submit a correction.

Researched ByDr. Parmis · Medical Researcher · Western University of Health Sciences

Medically Reviewed ByDr. Jonathan Snipes, MD · Kim Callender, NP (FNP-BC)

Last medically reviewed: · This page is informational and does not constitute medical advice.